AUS
NZ
UK
CA
USA
IND
Highlights
- Immuron has developed IMM-124E (Travelan®) leveraging its polyclonal antibody platform.
- Travelan® is positioned as a preventive solution for travelers’ diarrhea caused by bacterial pathogens.
- The product is approved or licensed across key markets, including Australia, Canada, and the United States.
- IMM-124E contains antibodies derived from hyper-immune bovine colostrum, enabling targeted gut activity.
- Backed by a scalable immunotherapy platform, Travelan® anchors Immuron’s strategy to expand orally delivered treatments for infectious diseases.
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is positioning IMM-124E (Travelan®) at the centre of its commercial strategy, targeting a widespread yet often underestimated risk for global travellers—travelers’ diarrhea. With millions of people moving across borders each year, exposure to unfamiliar pathogens remains a persistent concern, creating a compelling case for preventive solutions that act before symptoms emerge.
Travelan® holds different regulatory classifications across markets. In Australia, it is listed on the Australian Register for Therapeutic Goods and indicated for reducing the risk of travelers’ diarrhea and minor gastrointestinal disorders. In Canada, it is licensed as a natural health product, while in the United States, it is marketed as a dietary supplement for digestive tract protection.
A Preventive Approach to a Common Travel Risk
Travelers’ diarrhea is one of the most frequent health concerns for individuals visiting lower- and middle-income regions. Clinically defined as three or more unformed stools within 24 hours, often accompanied by additional symptoms, the condition is primarily linked to bacterial pathogens such as E. coli, Campylobacter, and Shigella.
IMM-124E (Travelan®) is designed as a prophylactic solution, aiming to reduce the risk of infection rather than treating symptoms after onset. The product works by binding to diarrhea-causing bacteria when consumed with meals, limiting colonization and associated gastrointestinal effects.
Mechanism of Action
IMM-124E is derived from the colostrum of cattle immunised during pregnancy with vaccines containing antigens from multiple human-derived enterotoxigenic E. coli (ETEC) strains. A total of 13 ETEC strains are used in this process to generate high levels of antibodies targeting common bacterial surface antigens.
These polyclonal antibodies demonstrate binding and neutralizing activity against lipopolysaccharide (LPS) antigens, including both variable and conserved regions. The final formulation is manufactured into tablet form and marketed as Travelan®.
Market Opportunity
The company highlights that the global travelers’ diarrhea market is estimated at approximately $3.31 billion for 2026, with a projected CAGR of approximately 6.8%. Bacterial pathogens account for around 80% of cases, aligning directly with Travelan®’s mechanism of action.
The prevention segment represents roughly 25% of the market, as many travelers rely on treatment after symptoms occur. A significant portion of international travel—estimated at 20–40%—involves movement from developed to higher-risk regions, forming the core addressable population.
The serviceable obtainable market is linked to increasing adoption of preventive solutions, supported by strategies such as early-stage consumer targeting and pharmacy engagement.
Platform Technology Behind Travelan®
Immuron’s broader platform is based on orally delivered polyclonal immunoglobulins derived from hyper-immune bovine colostrum. This approach enables targeted antibody delivery within the gastrointestinal tract without systemic absorption, forming the basis for IMM-124E and other potential applications.
Strategic Positioning
IMM-124E represents a key application of Immuron’s platform technology, translating antibody-based science into a commercial product addressing a clearly defined and globally relevant use case. By focusing on prevention rather than treatment, Travelan® is positioned within a distinct segment of the travelers’ diarrhea market.
The product’s formulation, regulatory footprint, and commercial performance collectively outline its role within Immuron’s broader strategy of developing orally delivered immunotherapies for infectious diseases.
Shares of IMC traded at AUD 0.027 on 13 April 2026.
